NRIX Nurix Therapeutics, Inc.
$25.10▼ -2.75%
Healthcare
Other
After hours
$25.10▲ +0.00%
Sep 11, 7:30 PM ET
Volume 1.32M
Avg Volume (10D) 1.27M
Key Metrics & Fundamentals
Market Cap
$2.60B
P/E Ratio
–
Div Yield
–%
52W Range
8.20 - 28.23
% vs 50 MA
0.19%
% vs 200 MA
31.23%
RSI-14
44.4
MACD Histogram
-0.2500
Beta (1Y vs SPY)
1.48
Free Cash Flow
-$98.51M
Gross Rev
$9.04M
Gross Profit
$9.04M
EBITDA
-$90.35M
COGS
–
Operating Exp
$103.25M
Operating Income
-$94.20M
EBIT
-$94.20M
Pretax Income
-$89.81M
Net Income
-$89.54M
EPS (Diluted)
-0.81
Price & Volume History
Loading chart…
Recent News
Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why
Zacks · Sep 9, 2026 4:00 PM
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
Zacks · Sep 3, 2026 3:50 PM
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire · Sep 1, 2026 12:00 PM
BeOne Medicines' Tacabrutideg Presents 'Sizable Opportunity' in CSU, RBC Says
MT Newswires · Aug 25, 2026 3:12 PM
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
GlobeNewswire · Aug 20, 2026 11:00 AM
Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says
MT Newswires · Aug 10, 2026 4:44 PM
RBC Adjusts PT on Nurix Therapeutics to $36 From $33, Maintains Outperform Speculative Risk Rating
MT Newswires · Aug 10, 2026 10:57 AM
Nurix Therapeutics (NRIX) Lands $10 Million Milestone As Phase 3 Trial Begins
Simply Wall St. · Aug 5, 2026 9:17 PM
Nurix Therapeutics Gets $10 Million Milestone Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader
MT Newswires · Aug 4, 2026 4:08 PM
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
GlobeNewswire · Aug 4, 2026 11:00 AM
Financial Overview - Income Statement
Quarterly
May 2026
See NRIX's money flow as a full page
Social Sentiment
No Reddit posts found for NRIX.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.